US · COAG · BIOTECHNOLOGY
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) intrinsic value and stock valuation
$39.29as of 2026-11-21 · Mkt cap 100.62M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Hemab Therapeutics Holdings, Inc. Common Stock DCF and intrinsic value
InvestorsCraft values COAG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from COAG’s statements →
Hemab Therapeutics Holdings, Inc. Common Stock Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2025–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | |
|---|---|
| Revenue | $0.00 |
| Operating income | -$-70.12M |
| Net income | -$-63.91M |
| EPSd | -$-2.33M |
| Operating cash flow | -$-61.48M |
| Capital expenditure | -$-20K |
| Free cash flow | -$-61.49M |
| Total assets | $194.8M |
| Total debt | $1.22M |
| Net debt | -$-86.75M |
| Total equity | -$-176.63M |
| Cash and short-term investments | $185.5M |
Income statement
| 2025 | |
|---|---|
| Revenue | $0.00 |
| Cost of revenue | $0.00 |
| Gross profit | $0.00 |
| Research and development expenses | $59.6M |
| Selling, general and administrative expenses | $10.5M |
| Other expenses | $0.00 |
| Operating expenses | $70.1M |
| Cost and expenses | $70.1M |
| Interest income | $1.97M |
| Interest expense | $0.00 |
| Depreciation and amortization | $300K |
| Ebitda | -$-69.81M |
| Operating income | -$-70.12M |
| Total other income/expenses, net | $5.98M |
| Income before tax | -$-64.14M |
| Income tax expense | -$-230K |
| Net income | -$-63.91M |
| Weighted average shares outstanding | $27.4M |
| Weighted average diluted shares outstanding | $27.4M |
Balance sheet
| 2025 | |
|---|---|
| Cash and short-term investments | $185.5M |
| Net receivables | $2.63M |
| Inventory | $0.00 |
| Total current assets | $192.6M |
| Property, plant and equipment, net | $1.7M |
| Goodwill and intangible assets | $0.00 |
| Long-term investments | $0.00 |
| Total non-current assets | $2.23M |
| Total assets | $194.8M |
| Accounts payable | $5.73M |
| Short-term debt | $650K |
| Deferred revenue | $0.00 |
| Total current liabilities | $10.7M |
| Long-term debt | $570K |
| Deferred revenue, non-current | $0.00 |
| Total non-current liabilities | $360.7M |
| Capital lease obligations | $1.22M |
| Total liabilities | $371.4M |
| Common stock | $130K |
| Retained earnings | -$-181.86M |
| Accumulated other comprehensive income (loss) | $170K |
| Total equity | -$-176.63M |
| Total investments | $97.5M |
| Total debt | $1.22M |
| Net debt | -$-86.75M |
Cash flow statement
| 2025 | |
|---|---|
| Net income | -$-63.91M |
| Depreciation and amortization | $300K |
| Stock-based compensation | $2.01M |
| Change in working capital | $1.35M |
| Accounts receivable | $0.00 |
| Inventory | $0.00 |
| Accounts payable | $2.58M |
| Net cash provided by operating activities | -$-61.48M |
| Investments in property, plant and equipment | -$-20K |
| Acquisitions, net | $0.00 |
| Net cash used for investing activities | -$-81.48M |
| Common stock issued | $0.00 |
| Common stock repurchased | $0.00 |
| Dividends paid | $0.00 |
| Net cash used for financing activities | $156.3M |
| Net change in cash | $13.6M |
| Cash at end of period | $88M |
| Operating cash flow | -$-61.48M |
| Capital expenditure | -$-20K |
| Free cash flow | -$-61.49M |
Line items
Line items
Line items
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
- CEO
- Benny Sorensen
- Employees
- 59
- Beta
- 1.85
Explore
Frequently asked questions
What is the intrinsic value of Hemab Therapeutics Holdings, Inc. Common Stock (COAG)?
InvestorsCraft does not currently publish an intrinsic value for COAG. How the IC value is calculated.
Is COAG undervalued?
InvestorsCraft does not publish an undervaluation signal for COAG at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.